Illumina Earnings: A Beat and a Raise
Date Published: 10-23-2018
DisclaimerThe results here are provided for general informational purposes, as a convenience to the readers. The materials are not a substitute for obtaining professional advice from a qualified person, firm or corporation.
This is a snippet taken form a full CML Pro dossier.
LEDESpotlight Top Pick Illumina (ILMN) reported earnings after the bell, and it was a beat and a raise across the board.
We added Illumina to Top Picks on 6-Apr-16 for $168.36. The stock is trading at $313.80, up 86.4% as of this writing.
Illumina - By the NumbersHere are the estimates and the actual results for the marvel that is Illumina.
Current Quarter Analyst Estimates
Illumina reported $1.52 in adjusted EPS, which not only beat the consensus average estimate of $1.26, but blew through the highest estimate of any analyst, which was $1.40. Further, Illumina reported $853 million in sales, beating the average estimate $828 million forecast and also smashing through even the highest estimate of $842.50 million.
The news got better.
Expected Guidance for Full Year:
Illumina crushed guidance as well, forecasting $5.70-$5.75 in adjusted EPS, compared with the average estimate of $5.42, and falling just shy of the highest full year estimate, which came in at $5.79.
What HappenedIf you want to win, you need to have the right data, at the right time, and it needs to be accurate.
You are on the better, smarter, faster version of finance portals like Yahoo! Finance. Welcome -- as one example, all of this data we just covered is available for any company, at any time, on the CMLviz.com Analyst Tab, for free: Right Here
Bookmark the site -- this is -- Free. Forever. Period.
The information contained on this site is provided for general informational purposes, as a convenience to the readers. The materials are not a substitute for obtaining professional advice from a qualified person, firm or corporation. Consult the appropriate professional advisor for more complete and current information. Capital Market Laboratories ("The Company") does not engage in rendering any legal or professional services by placing these general informational materials on this website.
The Company specifically disclaims any liability, whether based in contract, tort, strict liability or otherwise, for any direct, indirect, incidental, consequential, or special damages arising out of or in any way connected with access to or use of the site, even if we have been advised of the possibility of such damages, including liability in connection with mistakes or omissions in, or delays in transmission of, information to or from the user, interruptions in telecommunications connections to the site or viruses.
The Company make no representations or warranties about the accuracy or completeness of the information contained on this website. Any links provided to other server sites are offered as a matter of convenience and in no way are meant to imply that The Company endorses, sponsors, promotes or is affiliated with the owners of or participants in those sites, or endorse any information contained on those sites, unless expressly stated.